Skip to content

Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage

Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05502874
Acronym
CATCH
Enrollment
1600
Registered
2022-08-16
Start date
2022-09-01
Completion date
2025-10-01
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhage, Hemorrhagic Stroke, Intracerebral Hemorrhage, Neurologic Deficits

Keywords

Intracerebral Hemorrhage, Neurological Deterioration, Neuroimaging, Prognosis

Brief summary

This multicenter observational study will explore the risk factors of early neurological deterioration(END) in patients with primary and to investigate the association between END and outcome.

Detailed description

Neurological deterioration affects approximately one-third of patients with primary intracerebral hemorrhage (ICH) and increases the risk of death and dependency. However, the risk factors of early neurological deterioration (END), such as biochemical parameters, neuroimaging, and systemic complications, are not well documented in primary ICH, and the effective predictors of END is unknown. This multicenter observational study aims to seek out the risk factors of END in patients with primary ICH and to investigate the association between END and outcome.

Interventions

None listed

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Confirmed diagnosis of primary intracerebral hemorrhage

Exclusion criteria

* Patients with secondary * Undergo surgical evacuation of hematoma; * Presenting contraindications or refusal to MRI * Is pregnant * Patients refuse to be followed up for any reasons.

Design outcomes

Primary

MeasureTime frameDescription
Early neurological deterioration (END)48 hours after admissionEND is defined as an increase in the total NIHSS score of ≥ 4 points within the first 48 h after admission

Secondary

MeasureTime frameDescription
Functional outcome90 days, 1 year, 2 years after admissionFunctional outcome will be assessed with modified ranking scale(mRS).Poor outcome is defined as mRS 4-6 at follow-up
Hematoma expansion24 hours after admissionHematoma volume expansion of at least 6 mL or 33% on a CT scan obtained 24 hours after admission compared with the entry scan.
Late neurological deterioration (LND)7 daysLND is defined as an increase in the total NIHSS score of ≥ 4 points between 48h and 7 days after admission
Depression status90 days, 1 year, 2 years after admissionPatient Health Questionnaire (PHQ)-9 scale will be evaluated, and higher scores means a worse status.
Cognitive function90 days, 1 year, 2 years after admissionTelephone Interview for Cognitive Status-Modified(TICS-m) scale will be evaluated via telephone interview.
The quality of life90 days, 1 year, 2 years after admissionThe quality of life will be assessed with the EuroQol-5D (EQ-5D) scale.

Countries

China

Contacts

Primary ContactFeng Gao, MD,PhD
2202012@zju.edu.cn13588451471
Backup ContactLusha Tong, MD,PhD
2310040@zju.edu.cn15868171218

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026